Skip to content

Short term effects of adaptive servoventilation and continuous positive airway pressure in patients with central sleep apnea and Cheyne-Stokes Respiration

Short term effects of adaptive servoventilation and continuous positive airway pressure in patients with central sleep apnea and Cheyne-Stokes Respiration

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00013707
Enrollment
60
Registered
2018-03-16
Start date
2018-04-01
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

I50.1 I50.0

Interventions

Group 1: In 20 patients with predominantly central sleep apnoea (CSA) due to right sided heart failure due to Nizza class I pulmonary arterial Hypertension (PAH) an attended overnight titration of ade

Sponsors

Klinik für Schlafmedizin und neuromuskuläre Erkrankungen Universitätsklinikum Münster
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: a. Age > 18 years (no age limit) (Group 1, 2 and 3) b. able to consent (Group 1, 2 and 3) c. predominant central sleep apnoea as defined as AHI>15/h and >50% central events and a central AHI >10/h derived from full overnight attended polysomnography (Group 1, 2 and 3) d. Diagnosis of Nizza class I pumonary arterial Hypertension -PAH- and heart failure with reduced ejection fraction -HFrEF- according to the most recent Guidelines of the European Society of Cardiology (ESC); >12 weeks since the diagnosis of HFrEF / PAH has been made; no hospitalisation for HF in the last 4 weeks; optimal medical therapy in accordance with the most recent Guidelines of the European Society of Cardiology (ESC) with no change in medication in the last 4 weeks and combination therapy for both PAH and HFrEF -where there was no treatment with combination therapy in PAH patients or with beta blockers or ACE Inhibitors/ARBs in HFrEF, then the reason must be documented-) (Group 1 and 2) e. Controls (matched for age and gender) with idopathic central sleep apnoea with normal findings on echocardiogram, electrocardiogram and normal levels of natriuretic peptide hormone (Group 3)

Exclusion criteria

Exclusion criteria: - other severe internistic pre-existing conditions, especially insulin-dependent diabetes or severe renal impairment -intake of opiods - severe psychiatric pre-existing conditions

Design outcomes

Primary

MeasureTime frame
Mean heart rate [bpm], high frequency component of heart rate variability [%], low frequency component of diastolic blood pressure variability [%]

Secondary

MeasureTime frame
Systolic blood pressure [mmHG], diastolic blood pressure [mmHG], stroke volume index [L/min/m²], high frequency component of diastolic blood pressure variability[%], low frequency component of heart rate variability [%], respiratory rate [/min], tidal volume [ml], minute ventilation [L/min], oxygen saturation [%], transcutaneous CO2 [mmHG], sleep stage Non-Rem I [%], sleep stage Non-Rem II [%], sleep stage Non-Rem III [%], sleep stage REM [%], Awake [%], Arousal Index [/h]

Countries

Germany

Contacts

Public ContactJens Spiesshoefer

Klinik für Schlafmedizin und neuromuskuläre Erkrankungen Universitätsklinikum Münster

jens.spiesshoefer@ukmuenster.de00492518341119

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026